Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

To compare the postprandial glucodynamics of Humalog Mix25, (Humalog Mix75/25 in the US; Mix25), to human insulin 30/70 (Humulin 70/30 in the US; 30/70) in patients with type 1 or type 2 diabetes.

Why It Was Studied

Two-hour postprandial glucose (2pp), 2-hour glucose excursion (2pp(ex) ), glucose versus time area under the curve 0 to 4 hours (AUC(0-4) ) and glucose excursion area under the curve 0 to 2 and 0 to 4 hours (AUCex(0-2), AUCex(0-4) ) were calculated.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Ninety-three patients with type 1 diabetes and 84 patients with type 2 diabetes were evaluated in two separate but identical protocols using a randomized, multicenter, double-blind, crossover design.

How the Study Was Run

The researchers set it up as a randomized, double-blind, crossover and multicenter study.

The participants were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Insulin Lispro.

In the crossover set-up each of the participants took both Insulin Lispro and the comparison in turn, acting as their own control.

More than one site took part, so the participants came from several places.

What Was Measured

Topics PubMed links to this paper include Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Fasting, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro.

The publication is from 2000 (Diabetes & metabolism), a journal based in France.

More context: the Insulin Lispro compound page, all human trials.